Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yep. It’s happening.
Give it a rest boys. Let’s just see what happens.
The big question will be what the stock price will be after a liquidity event. And if it is less than $.05 will Ken stick to his commitment on not doing the RS and uplist below a $.05 price.
I was encouraged by the latest podcast. Glad they said they would not add the 2B shares that were authorized. That tells me they expect to have funds without further dilution prior to any uplist. I liked hearing that, the revenue growth and his confidence in the two liquidity through acquisition (MJ Link) and SPAC (for Huntpost).
Also looking forward to hearing their investor presentations around October 11. That will be good assuming they will be in a quiet period until the Q3 ER is released, which I also liked hearing may be end of October.
They are estimating the proceeds at $7.8MM.
They have estimated the use of proceeds among the various solutions.
It is pretty clear the number one priority of the use of funds will be around Metformin and AMD.
They clearly state below $3.0MM for Metformin/AMD. Even if they spend $2.4MM on G&A, this will give them plenty of runway to monetize Metformin. And of course all forecasted expenses are “estimates” until they are actually made, including the $200k per month G&A.
Retinal Degeneration
We estimate that it will cost approximately $2.0 million in pre-clinical, IND-enabling studies, manufacturing, and other costs related to submitting an IND application. Provided we are able to receive IND approval, we estimate that it will cost approximately an additional $1.0 million to conduct and complete a phase 1 clinical trial of dry age-related macular degeneration (AMD) and Geographic Atrophy. Pursuant to the CRADA (see section of this Prospectus entitled “Product Development” – Degenerative Eye Diseases” for more information), our contribution to the first clinical trial will be a maximum of $115,000, with the balance to be covered by the National Eye Institute.
I looked at many posts (I would consider that looking a little harder as you suggested). Your post yesterday is the only one I saw about no warrants. I find the timing of your comment yesterday interesting considering the new S1 came out today without mention of warrants.
Your links took me to a blank page in iHub. I’ll take your word for it. Thanks for the links. Hope the warrants stay out of the mix.
How could no warrants not be a positive? Less dilution, correct?
I see no posts along that line. The S1 today is different from the one earlier in the month.
The new prospectus makes no mention of warrants either, just 1,553,398 shares of common stock. Unless I am reading this wrong, seems the terms are different.
You wanted it at .0088 and you got it. I will be buying right along with you.
Many here will be singing a different tune in 30 days once the dust settles and we actually know the terms of the deal, and some news gets released right after provoking fear to drive sellers to a price they will then gobble up. I’m a buyer. A big buyer down here.
Probably be 1M after the uplist to AMEX. Any good news, and there will be much imo, will send this thing flying.
My hunch is you are wrong. I think they get the S1 done.
I have asked the question, multiple times. And for me I am not as interested in the pre-split RS ratio but rather on the market cap which is about $15M. I personally cannot change the price of the stock nor can the IR guy. I personally feel the upside value is high compared to the current market cap. That’s why I am here. I can piss and moan all day long and make posts that make me feel intellectually superior but at the end of the day nothing you or I can do will change anything. That is the difference between you and me. I realize that you and you don’t. If you feel so bad about the company why do you still own 2M shares (seems you been selling some shares since the last time you reported 3M).
Let me be clear. Those words make me feel powerful. You will be proven wrong. And I will be looking for the “I was wrong” post when it happens.
Good points! It would be nice to see that MJ Link acquisition.
You know there is market manipulation to hold price down when you put in an order at .0265 and they sell it to you at .026. That just happened to me.
You know there is manipulation to hold the price down when you put in a bid at .0265 and they sell it to you at .026. Anything under .03 I think is a good price. I’ll take it.
I know Steve from the calls I’ve had with him. He seems like a straight shooter; he never avoids the tough questions, of which I have asked many. I don’t post my questions here and rely on others to answer them. When I’ve have questions I go to the source. Then I keep the answers to myself, because I’m doing the work and due diligence. Good luck to you.
I hope there is news before the next podcast. If I recall the next podcast will be the last one before another quiet period. I think said two podcasts before next quiet period. If nothing substantial comes out by 9/31, likely to linger here until 11/1. At that time the pressure will be on to get a liquidity event done by EOY. He will have 60 days to deliver.
No IR person is going to answer a question by email on any trading by insiders. NO ONE. Calling the IR person is the right way to approach this. Steve is very responsive and will answer all questions he is able to.
Good time for those insiders who are selling to sell. Why not sell here versus the low .02’s when someone here suggested they were selling, which of course they weren’t. . LOL.
There is no way he realizes the value. No way possible.
Insiders aren’t selling. No reason to when they are close to the S1 and uplist. It would not be smart for insiders to sell after all they have put into this. You and I know this but others can choose to believe what they want.
Not what I’m thinking at all. Who would be buying if insiders are selling, which as has has been reported ad nauseum here they can’t do. Unlikely scenario.
Jiddy is it confirmed the reduction was from one of the cases? Good information. Thanks!
Fair enough.
And if the S1 becomes effective what will your response be?
We was in another stock that did a RS. It happened after hours after close and I was reading it the next day. It won’t take a couple days.
No that is not is what is going to happen at all.
So when you say the story here is uncompelling you are saying that owning the worldwide licensing rights for a Metformin eye drop formula to treat AMD when the main current treatment is a needle injection in the eye, is of no value. Given the size of the wet and dry AMD market to be in the multi billions with an ever aging population, some pharma company will see value in this and want to take it to market if trials prove effective. I disagree with your assessment but that is the beauty of a free market system. I think the demand will be there for this solution.
They won’t. RS won’t happen without the uplist.
No I don’t. It ain’t easy to uplist. Patience will pay off.
You’re right. He won’t because I will be buying what he doesn’t pick up. Buying every day until the S1 goes effective. How many shares you willing to sell to get this to .008?
Good price I think.
Stole a few at .0228 today.
I think I’d prefer an eye drop. Anyone know of any companies producing an eye drop to treat AMD? Seems like a nice solution compared to injections and now surgical implants.
The next podcast is on 9/21/22 at 3:00PM. There is a placeholder on their YouTube channel. I’m sure the 8K is forthcoming.
Why don’t you call the IR guy and ask the question.
Sounds like a good plan.